Page last updated: 2024-12-11
1-stearoyl-2-oleoyl-sn-glycerol
Description
## 1-Stearoyl-2-Oleoyl-sn-glycerol (18:0/18:1)
1-Stearoyl-2-Oleoyl-sn-glycerol, also known as **18:0/18:1**, is a **triglyceride**, a type of fat molecule. It's composed of:
* **Glycerol:** A three-carbon alcohol backbone.
* **Stearic acid:** A saturated fatty acid with 18 carbon atoms.
* **Oleic acid:** An unsaturated fatty acid with 18 carbon atoms and one double bond.
The specific arrangement of fatty acids on the glycerol backbone is what makes it **1-Stearoyl-2-Oleoyl-sn-glycerol**. The sn in the name refers to the stereochemical configuration of the glycerol molecule.
**Importance in Research:**
1-Stearoyl-2-Oleoyl-sn-glycerol, like many other triglycerides, is a crucial component of **lipid metabolism**. It plays a role in:
* **Energy storage:** Triglycerides are the primary form of energy storage in the body.
* **Cell membrane structure:** Phospholipids, which are similar to triglycerides but with a phosphate group attached, are crucial for forming cell membranes.
* **Signaling pathways:** Some lipids, including triglycerides, act as signaling molecules, affecting cellular processes.
**Research Applications:**
1-Stearoyl-2-Oleoyl-sn-glycerol has been used in various research areas, including:
* **Lipid metabolism studies:** Studying how the body breaks down and utilizes triglycerides, including its role in obesity and diabetes.
* **Cell membrane research:** Understanding the composition and function of cell membranes, particularly in relation to diseases like cancer.
* **Nutritional studies:** Investigating the impact of dietary fats on health and disease.
* **Drug development:** Exploring the potential of triglycerides as drug targets or carriers.
**Further Research:**
While the basic structure and function of triglycerides are well-understood, ongoing research is exploring more specific aspects of 1-Stearoyl-2-Oleoyl-sn-glycerol, such as:
* Its interactions with other lipids and proteins.
* Its specific role in various cell types and tissues.
* Its potential as a biomarker for certain diseases.
Overall, 1-Stearoyl-2-Oleoyl-sn-glycerol is an important molecule for understanding lipid metabolism, cell function, and disease pathogenesis. Further research will shed more light on its specific role in various physiological and pathological processes.
1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol : A 1,2-diacyl-sn-glycerol that has stearoyl and oleoyl as the 1- and 2-acyl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 6443547 |
CHEBI ID | 75468 |
SCHEMBL ID | 7917740 |
MeSH ID | M0223812 |
Synonyms (25)
Synonym |
1-octadecanoyl-2-(9z-octadecenoyl)-sn-glycerol |
LMGL02010043 , |
dg(18:0/18:1(9z)/0:0)[iso2] |
dg(18:0_18:1) |
dg(18:0/18:1/0:0)[iso2] |
[(2s)-3-hydroxy-2-[(z)-octadec-9-enoyl]oxypropyl] octadecanoate |
1-stearoyl-2-oleoyl-sn-glycerol |
sn-sodg |
9-octadecenoic acid (z)-, 1-(hydroxymethyl)-2-((1-oxooctadecyl)oxy)ethyl ester, (s)- |
53702-48-0 |
1-octadecanoyl-2-[(9z)-octadecenoyl]-sn-glycerol |
(2s)-1-hydroxy-3-(octadecanoyloxy)propan-2-yl (9z)-octadec-9-enoate |
CHEBI:75468 |
SCHEMBL7917740 |
dg(18:0/18:1(9z)/0:0) |
dag(18:0/18:1n9) |
diacylglycerol(18:0/18:1n9) |
dg(18:0/18:1n9) |
dg(18:0/18:1w9) |
diacylglycerol(18:0/18:1w9) |
dag(18:0/18:1w9) |
1-steraoyl-2-oleoyl-sn-glycerol |
Q27105044 |
DTXSID301150231 |
(1s)-1-(hydroxymethyl)-2-[(1-oxooctadecyl)oxy]ethyl (9z)-9-octadecenoate |
Roles (1)
Role | Description |
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
1,2-diacyl-sn-glycerol | |
1-stearoyl-2-oleoylglycerol | A 1,2-diglyceride with stearoyl and oleoyl as the acyl groups. |
diacylglycerol 36:1 | A diglyceride in which the two acyl groups contain a total of 36 carbons and 1 double bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathways (43)
Pathway | Proteins | Compounds |
phospholipid biosynthesis (PE(18:0/18:1(9Z))) | 7 | 17 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/16:0) | 5 | 12 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:0) | 5 | 12 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(9Z)) | 5 | 12 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(11Z)) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:2(9Z,12Z)) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z)) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z)) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:0) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(11Z)) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(13Z)) | 5 | 12 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:0) | 5 | 13 |
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:1(13Z)) | 5 | 13 |
Phosphatidylcholine Biosynthesis PC(18:0/18:1(9Z)) | 6 | 20 |
Phosphatidylethanolamine Biosynthesis PE(18:0/18:1(9Z)) | 5 | 16 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:0) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:1(9Z)) | 5 | 13 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:1(11Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:2(9Z,12Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:0) | 5 | 13 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:0) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/24:0) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/14:1(9Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/16:1(9Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:1(11Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:3(5Z,8Z,11Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:1(13Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/24:1(15Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:2(13Z,16Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:4(7Z,10Z,13Z,16Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/18:4(6Z,9Z,12Z,15Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:4(8Z,11Z,14Z,17Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | 5 | 14 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:2(11Z,14Z)) | 5 | 13 |
De Novo Triacylglycerol Biosynthesis TG(18:0/18:1(9Z)/20:3(8Z,11Z,14Z)) | 5 | 13 |
Lipids measured in liver metastasis from breast cancer | 6 | 29 |
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/18:1(9Z)) | PE(18:0/18:1(9Z)) | 6 | 17 |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.36 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.31 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |